Home › NCT05774704
Curcumin and Retinal Study
RecruitingPhase 1/2Healthy volunteers welcome
Curcumin and Retinal Amyloid-beta Pilot Study
Who can join
Ages 40 to 89 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion: * Both male and female, age 40 - 89 years. * Diagnosed with Aβ deposits in retina (peripheral superior quadrants)--to be confirmed after consent obtained. If there is documentation the potential participant has been diagnosed with Aβ deposits in retina within 6 months before the consent session, we will use this diagnosis/documentation for eligibility criteria. Otherwise, the ophthalmic exam will be repeated after consent is obtained for the study. * No pre-existing liver or kidney diseases by self-report. Exclusion: * Patients with ocular diseases (macular degeneration, severe diabetes retinopathy) * Had used systemic antibiotics within 1 month prior to the start of the study intervention * Had taken any turmeric or curcumin products within 2 weeks prior to the start of the study intervention * Had a known allergy to black pepper * Women that are pregnant or breastfeeding
About the study
To test how two weeks of curcumin supplementation would cross the blood brain barrier (BBB) and attach to amyloid beta proteins, to assess the feasibility (safety and bioavailability), and to explore the resulting abundance/composition of gut microbiota.
What is being tested
- Low curcumin group (drug)
- High curcumin group (drug)
Sponsor: Texas Tech University Health Sciences Center · Participants: 60 · Started: Aug 21, 2023
Contact the study team
- Chwan-Li (Leslie) Shen, PhD · Phone: 8067432815
Official record on ClinicalTrials.gov — NCT05774704
Locations in the U.S.
| Texas | Texas Tech University Health Sciences Center, Lubbock |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.